Aardvark Therapeutics, Inc.

AARD · NASDAQ

Official-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.

Follow Add to Watchlist Ask Question

NASDAQ AARD Coverage Bootstrap Biotechnology Metabolic Disease Prader-Willi Syndrome

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.